Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on March 19, 2019, covering events occurring on March 18, 2019. The filing reports the election of a new director and the appointment of a member to the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
The Board of Directors increased its size by one member and elected Mitchell Levinson to fill the vacancy, effective immediately. Mr. Levinson was also appointed to the Audit Committee. He previously served on the Board from January 2015 to November 2017.
Management Commentary and Compensation
Mr. Levinson brings over 25 years of experience in medical device executive management, product development, and regulatory strategy. His prior roles include CEO of Zeltiq Aesthetics Inc. and CTO of Cerebrotech Medical Systems. His compensation package includes:
- Annual retainer of $35,000.
- Annual Audit Committee retainer of $7,500.
- Initial stock option grant for 35,000 shares vesting over three years.
- Annual stock option grant for 15,000 shares vesting monthly over one year, commencing at the first annual meeting after the initial award.
Mr. Levinson will execute the Company's standard indemnification agreement. No related party transactions or family relationships with other directors or officers were reported.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 35,000 initial stock options granted to Mr. Levinson.
- Confirm the date of the 2019 annual meeting of stockholders to determine the term expiration for Mr. Levinson.
- Review the Company's equity compensation plan to ensure the grants comply with available share reserves.
- Check for any subsequent filings regarding the composition of the Audit Committee.